Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon

PHASE4UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2017

Conditions
Atrial FibrillationLeft Atrial Thrombosis
Interventions
DRUG

Dabigatranetexilate

After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.

DRUG

Phenprocoumon

After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.

Trial Locations (1)

89081

RECRUITING

Department of Internal Medicine II, University Hospital Ulm, Ulm

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

University of Ulm

OTHER

NCT02591225 - Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon | Biotech Hunter | Biotech Hunter